Sign in to view content

Extended Q16W Dosing Potential for Faricimab in Neovascular Age-Related Macular Degeneration (nAMD): STAIRWAY Phase 2 Trial

Philip J. Ferrone, MD, FASRS

Video
Published 2019

Phillip J. Ferrone, MD

AMD Neovascular Part I Symposium

Related

Ixoberogene Soroparvovec (Ixo-vec) IVT Gene Therapy for Neovascular AMD: First-Time 26-Week Interim Analysis Results From the Phase 2 LUNA Study
Charles C Wykoff, MD, PhD, FASRS
Annual Meeting Talks
2024
Aflibercept 8 mg for Diabetic Macular Edema: 2-Year Results of the Phase 2/3 PHOTON Trial
Diana V Do, MD, FASRS
Annual Meeting Talks
2023
Ixoberogene Soroparvovec (Ixo-vec) IVT Gene Therapy for Neovascular AMD: First Time 26-Week Interim Analysis Results from the Phase 2 LUNA Study
Charles C Wykoff, MD, PhD, FASRS
Updates from the Field
2024

Category: AMD-Neovascular

See more